Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILES-5: Immunotherapy vs Chemotherapy in Elderly Advanced NSCLC
NCT03975114Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03975114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975114.